All In Biotech

Drug Trial Radar · NCT01352663

Immunogenicity Safety Study of Wockhardt's Recombinant Insulin Analogue in Type 1 Diabetic Patients

An Open Label, Randomized Comparison of Wockhardt's Recombinant Insulin Analogue With Innovator's Glargine in Type 1 Diabetic Patients.

Last checked: Nov 20, 2026Latest source record: Oct 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

WithdrawnPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Withdrawn

Enrollment

0

Actual

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
WockhardtIndustry
Sponsor type
Industry
First posted
May 12, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, randomized, parallel group comparison of the immunogenicity safety of Wockhardt's Recombinant Insulin Analogue with the innovator's Glargine in Type 1 diabetics patients.

Conditions

  • Type I Diabetes

Interventions

  • Wockhardt's Insulin Analogue (Recomb)Biological

    Basal bolus Wockhardt's Recombinant Insulin Analogue to be injected subcutaneously.

  • Lantus®Biological

    Basal bolus Insulin analog glargine (Lantus®) to be injected subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbAlc from baseline till the end of treatment period.Time frame: 12 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.